WO2001040230A1 - Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine - Google Patents

Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine Download PDF

Info

Publication number
WO2001040230A1
WO2001040230A1 PCT/JP2000/008008 JP0008008W WO0140230A1 WO 2001040230 A1 WO2001040230 A1 WO 2001040230A1 JP 0008008 W JP0008008 W JP 0008008W WO 0140230 A1 WO0140230 A1 WO 0140230A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
salt
cyclo
pyrazine
Prior art date
Application number
PCT/JP2000/008008
Other languages
English (en)
Inventor
Atsushi Akahane
Satoru Kuroda
Hiromichi Itani
Seiichiro Tabuchi
Yoshiniro Sato
Nobuya Matsuoka
Miho Tada
Hideaki Matsuoka
Takuma Oku
Akira Tanaka
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to EP00974973A priority Critical patent/EP1244669A1/fr
Priority to AU13093/01A priority patent/AU1309301A/en
Priority to JP2001540985A priority patent/JP2003515537A/ja
Publication of WO2001040230A1 publication Critical patent/WO2001040230A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a novel compound and a salt thereof, which are useful as medicaments.
  • pyrazolopyridine compounds to be useful as psychostimulant, remedy for renal failure, or the like are known (e.g. EP-0299209, EP-0379979, EP-0467248, EP-0516941, etc.).
  • pyrazolopyrazine compounds are novel, so there has been no knowledge about these compounds.
  • the present invention relates to a novel pyrazolopyrazine compound and a pharmaceutically acceptable salt thereof, which are useful as medicaments; processes for the preparation of said pyrazolopyrazine compound and a salt thereof; a pharmaceutical composition comprising, as an active ingredient, said pyrazolopyrazine compound or a pharmaceutically acceptable salt thereof; a use of said pyrazolopyrazine compound or a pharmaceutically acceptable salt thereof as a medicament; and a method for using said pyrazolopyrazine compound or a pharmaceutically acceptable salt thereof for therapeutic purposes, which comprises administering said pyrazolopyrazine compound or a pharmaceutically acceptable salt thereof to a human being or an animal.
  • the pyrazolopyrazine compound and a salt thereof are adenosine antagonists (especially, A ! receptor and A 2 (particularly A 2a ) receptor dual antagonists) and possess various pharmacological actions such as anticatalepsy action, cognitive enhancing action, analgesic action, locomotor action, antidepressant action, diuretic action, cardioprotective action, cardiotonic action, vasodilating action (e.g.
  • cognitive enhancer useful as cognitive enhancer, antianxietry drug, antidementia drug, psychostimulant, analgesic, cardioprotective agent, antidepressant, ameliorants of cerebral circulation, tranquilizer, drug for heart failure, cardiotonic agent, antihypertensive agent, drug for renal failure (renal insufficiency) , drug for renal toxicity, renal protective agent, drug for improvement of renal function, diuretic, drug for edema, antiobesity, antiasthmatic, bronchodilator, drug for apnea, drug for gout, drug for hyperuricemia, drug for sudden infant death syndrome (SIDS) , ameliorants of immunosuppressive action of adenosine, antidiabetic agent, drug for ulcer, drug for pancreatitis, drug for Meniere ' s syndrome, drug for anemia; drug for thrombosis, drug for myocardial infarction, drug for obstruction, drug for arteriosclerosis obliterans, drug for
  • ischemia/reperfusion injury e.g. myocardial ischemia/reperfusion injury, cerebral ischemia/reperfusion injury, peripheral ischemia/re
  • SIRS systemic inflammatory response syndrome
  • multiple organ failure e.g. renal failure (renal insufficiency) (e.g. acute renal failure, etc. )
  • renal toxicity e.g. renal toxicity induced by a drug such as cisplatins, gentamicin, FR-900506 (disclosed in EP-0184162) , cyclosporin (e.g. cyclosporin A) or the like; glycerol, etc.], nephrosis, nephritis, edema (e.g.
  • cardiac edema cardiac edema, nephrotic edema, hepatic edema, idiopathic edema, drug edema, acute angioneurotic edema, hereditary angioneurotic edema, carcinomatous ascites, gestational edema, etc.
  • obesity bronchial asthma, gout, hyperuricemia, sudden infant death syndrome, immunosuppression, diabetes, ulcer such as peptic ulcer (e.g. gastric ulcer, duodenal ulcer, etc.), pancreatitis, Meniere's syndrome, anemia, dialysis-induced hypotension, constipation, ischemic bowel disease, ileus (e.g.
  • thrombosis e.g. arterial thrombosis, cerebral thrombosis, etc.
  • obstruction arteriosclerosis obliterans, thrombophlebitis, cerebral infarction, transient ischemic attack, angina pectoris, or the like.
  • novel pyrazolopyrazine compound of the present invention can be shown by the following formula (I) .
  • R is aryl which may have one or more suitable substituent (s) , and
  • R is hydrogen; lower alkyl; lower alkenyl; cyclo (lower) alkyl; heteromonocyclic group; or lower alkyl substituted with one or more substituent (s) selected from the group consisting of cyclo (lower) alkyl, halogen, cyano, aryl and heteromonocyclic group, or a salt thereof.
  • the object compound (I) or a salt thereof of the present invention can be prepared by the following processes.
  • Process 1
  • R 1 is as defined above
  • R is arylsulfonyl which may have one or more suitable substituent (s) ; di (lower) alkylamino; lower alkoxy; lower alkylthio; or acyloxy,
  • R a is lower alkyl; cyclo (lower) alkyl; lower alkyl substituted with cyclo (lower ) alkyl; lower alkyl substituted with aryl; heteromonocyclic group; or lower alkyl substituted with heteromonocyclic group,
  • R 4 and R 5 are each lower alkyl
  • X is a leaving group
  • the starting compound (II) or a salt thereof is novel and can be prepared, for example, by the following reaction schemes.
  • Tf 2 0 is trifluoromethanesulfonic anhydride.
  • the object compound (I) and a salt thereof can be prepared, for example, according to the procedures as illustrated in Examples in the present specification or in a manner similar thereto.
  • the starting compounds can be prepared, for example, according to the procedures as illustrated in Preparations in the present specification or in a manner similar thereto.
  • the object compound (I) and a salt thereof can be prepared according to the methods as shown in Preparations or Examples , or in a manner similar thereto.
  • the object compound (I) may include the geometrical isomer(s) due to the double bond(s) and/or the stereo isomer(s) due to the asymmetric carbon atom(s) .
  • one isomer can be converted to another according to a conventional method in this field of the art.
  • Suitable salts of the object compound (I) are conventional pharmaceutically acceptable ones and include a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt , N, N ' -dibenzylethylenediamine salt , etc.), an organic acid salt (e.g.
  • a metal salt such as an alkali metal salt (e.g. sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g. calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt , N, N ' -d
  • an inorganic acid salt e.g. hydrochloride, hydrobromide, hydriodide, sulfate, phosphate, etc.
  • a salt with an amino acid e.g. argimne, aspartic acid, glutamic acid, etc.
  • Suitable "lower alkyl” may include straight or branched ones such as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl or the like, in which the preferred one may be methyl, isopropyl or pentyl.
  • Suitable "lower alkenyl” may include straight or branched ones such as vinyl, allyl, lsopropenyl or the like, in which the preferred one may be vinyl.
  • Suitable "lower alkyl substituted with halogen” may include, for example, fluoromethyl, chloromethyl, bromomethyl, lodomethyl, fluoroethyl, chloroethyl, bromoethyl, lodoethyl, fluoropropyl, chloropropyl, bromopropyl, lodopropyl, difluoromethyl, dichloromethyl, dibromomethyl, dnodomethyl, difluoroethyl, dichloroethyl, dibromoethyl, dnodoethyl, difluoropropyl, dichloropropyl, dibromopropyl, dnodopropyl, trifluoromethyl, t ⁇ chloromethyl, t ⁇ bromomethyl, trnodomethyl, trifluoroethyl, trichloroethyl, tribromoethyl, trii
  • Suitable "aryl” may include phenyl, naphthyl, mdenyl, anthryl, and the like, in which the preferred one may be (C6- CIO) aryl, and the more preferred one may be phenyl.
  • the "aryl” mentioned above may have one or more (preferably 1 to 3) suitable substituent (s) selected from the group consisting of halogen (e.g. fluoro, chloro, bromo, lodo) , lower alkyl as mentioned above, lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, etc. ) , hydroxy, and the like.
  • suitable substituent selected from the group consisting of halogen (e.g. fluoro, chloro, bromo, lodo) , lower alkyl as mentioned above, lower alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy, etc. ) , hydroxy, and the like.
  • Suitable "cyclo (lower) alkyl” may be cyclo (C3-C8 ) alkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or the like, in which the preferred one may be cyclo (C5-C6) alkyl such as cyclopentyl or cyclohexyl.
  • Suitable "heteromonocyclic group” may include saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 hetero atom(s) selected from among oxygen, sulfur and nitrogen in its ring, in which the preferred one may be saturated 5 to 6-memberd heteromonocyclic group containing 1 to 2 oxygen atom(s) in its ring such as tetrahydrofuranyl or tetrahydropyranyl; or unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 hetero atom(s) selected from among oxygen, sulfur and nitrogen in its ring, in which the preferred one may be unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 hetero atom(s) selected from among oxygen, sulfur and nitrogen in its ring such as pyridyl, furanyl, thienyl and thiazolyl.
  • Suitable “a leaving group” may include halogen (e.g. fluoro, chloro, bromo and iodo) , hydroxy, acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.), sulfonyloxy (e.g. mesyloxy, tosyloxy, etc.), and the like.
  • halogen e.g. fluoro, chloro, bromo and iodo
  • hydroxy acyloxy such as alkanoyloxy (e.g. acetoxy, propionyloxy, etc.), sulfonyloxy (e.g. mesyloxy, tosyloxy, etc.), and the like.
  • Suitable “anion” may be formate, acetate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, chloride, bromide, iodide, sulfate, phosphate, or the like.
  • the compound (la) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to hydrolysis.
  • Suitable salt of the compound (II) can be referred to an acid addition salt as exemplified for the compound (I).
  • This reaction is carried out in accordance with a conventional method.
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamide (e.g. trimethylamine, triethylamine, etc.), hydrazine, picoline, 1, 5-diazabicyclo [ 4.3.0] non-5-ene, 1, 4-diazabicyclo [2.2.2]octane, 1 , 8-diazabicyclo [5.4.0] undec-7-ene, or the like.
  • an alkali metal e.g. sodium, potassium, etc.
  • an alkaline earth metal e.g. magnesium, calcium, etc.
  • trialkylamide e.g. trimethylamine, triethylamine, etc.
  • hydrazine picoline, 1, 5-diazabicyclo [ 4.3.0] non-5-ene, 1, 4-
  • Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).
  • organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
  • an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
  • Lewis acid such as trihaloacetic acid (e.g. trichloroacetic acid, trifluoroacetic acid, etc.) or the like is preferably carried out in the presence of cation trapping agents (e.g. anisole, phenol, etc.).
  • cation trapping agents e.g. anisole, phenol, etc.
  • the reaction is usually carried out in a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N, N-dimethylformamide, N,N- dimethylacetamide, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N, N-dimethylformamide, N,N- dimethylacetamide, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • a solvent such as water, an alcohol (e.g. methanol, ethanol, isopropy
  • a liquid base or acid can be also used as the solvent.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the compound (lb) or a salt thereof can be prepared by reacting the compound (la) or a salt thereof with the compound (III) or a salt thereof.
  • Suitable salt of the compound (la) can be referred to an acid addition salt as exemplified for the compound (I).
  • Suitable salt of the compound (III) can be referred to the ones as exemplified for the compound (I) .
  • the present reaction may be carried out in a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, methylene chloride, ethylene chloride, formamide, N, N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not adversely affect the reaction, preferably in ones having strong polarities.
  • a solvent such as water, phosphate buffer, acetone, chloroform, acetonitrile, nitrobenzene, methylene chloride, ethylene chloride, formamide, N, N-dimethylformamide, methanol, ethanol, sec-butanol, amyl alcohol, diethyl ether, dioxane, tetrahydrofuran, dimethyl sulfoxide, or any other organic solvent which does not
  • the reaction is preferably conducted in the presence of a base, for example, inorganic base such as alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride, organic base such as trialkylamine, and the like.
  • a base for example, inorganic base such as alkali metal hydroxide, alkali metal carbonate, alkali metal bicarbonate, alkali metal hydride, organic base such as trialkylamine, and the like.
  • the reaction temperature is not critical, and the reaction is usually carried out at ambient temperature, under warming or under heating.
  • the present reaction is preferably carried out in the presence of alkali metal halide (e.g. sodium iodide, potassium iodide, etc.), alkali metal thiocyanate (e.g. sodium thiocyanate, potassium thiocyanate, etc.), di (lower) alkyl azodicarboxylate (e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc . ) or the like .
  • alkali metal halide e.g. sodium iodide, potassium iodide, etc.
  • alkali metal thiocyanate e.g. sodium thiocyanate, potassium thiocyanate, etc.
  • di (lower) alkyl azodicarboxylate e.g. diethyl azodicarboxylate, diisopropyl azodicarboxylate, etc .
  • X is -OH
  • the compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to elimination reaction of alkyl group.
  • Suitable salts of the compound (Ic) and (Id) can be referred to the ones as exemplified for the compound (I). This reaction is carried out in accordance with a conventional method such as hydrolysis.
  • the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
  • Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), hydroxide or carbonate or bicarbonate thereof, trialkylamine (e.g. trimethylamme, t ⁇ ethylamine, etc.), hydrazine, picolme, 1, 5-d ⁇ azab ⁇ cyclo [4.3.0] non-5-ene, 1, 4-d ⁇ azab ⁇ cyclo [2.2.2] octane,
  • an alkali metal e.g. sodium, potassium, etc.
  • an alkaline earth metal e.g. magnesium, calcium, etc.
  • hydroxide or carbonate or bicarbonate thereof e.g. trimethylamme, t ⁇ ethylamine, etc.
  • trialkylamine e.g. trimethylamme, t ⁇ ethylamine, etc.
  • hydrazine picolme, 1, 5-d ⁇ azab ⁇
  • Suitable acid includes an organic acid (e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.) and an inorganic acid (e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).
  • organic acid e.g. formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
  • an inorganic acid e.g. hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
  • Lewis acid e.g. aluminium chloride, titanium trichloride, tin tetrachlo ⁇ de, etc.
  • cation trapping agents e.g. anisole, phenol, etc.
  • the reaction is usually carried out in a solvent such as water, alcohol (e.g. methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N, N-dimethylformamide, N,N- dimethylacetamide, or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
  • a liquid base or acid can be also used as the solvent.
  • reaction of this process can be also carried out according to a conventional reduction method employed in this field of the art (e.g. chemical reduction, catalytic reduction, etc.).
  • a conventional reduction method employed in this field of the art (e.g. chemical reduction, catalytic reduction, etc.).
  • reaction temperature is not critical and the reaction is usually carried out at ambient temperature, under warming or under heating.
  • the compound (If) or a salt thereof can be prepared by reacting the compound (Ie) or a salt thereof with the compound (IV) or a salt thereof.
  • Suitable salt of the compound (Ie), (IV) and (If) can be referred to the ones as exemplified for the compound (I) .
  • Step 3 The compound (II) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof with the compound (VIII). Suitable salts of the compounds (II) and (VII) can be referred to acid addition salts as exemplified for the compound (I).
  • the reaction is usually carried out in a solvent such as water, methylene chloride, ethylene chloride, N, N-dimethylformamide or any other solvent which does not adversely influence the reaction or a mixture thereof.
  • the reaction can be carried out in the presence of a base such as alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), ar (low.er) alkyltri (lower) alkylammonium halide (e.g. benzyltrimethylammonium chloride, etc.) or the like.
  • a base such as alkali metal hydroxide (e.g. sodium hydroxide, potassium hydroxide, etc.), ar (low.er) alkyltri (lower) alkylammonium halide (e.g. benzyltrimethylammonium chloride, etc.) or the like.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling, at room temperature or under warming .
  • the object compound (I) of the present invention is an adenosine antagonist and possesses the various pharmacological actions as stated before.
  • the pharmacological test result of the representative compound of the present invention is shown in the following .
  • Test 1 Adenosine antagonistic activity
  • the adenosine antagonistic activity [Ki(nM)] of the test compound was examined by radioligand binding techniques using 8-cyclopentyl-l, 3-dipropylxanthine, [dipropyl-2, 3- 3 H (N) ] ([ 3 H]DPCPX, 4.5n ) for human A*, receptor and [ 3 H] CGS 21680 (20nM) for human A 2a receptor.
  • Test compound Manifestation rate of catalepsy (Example No. ) (number of mouse) 1/7 0/7
  • the pyrazolopyrazine compound (I) and a salt thereof of this invention are useful as adenosine antagonists (especially, A L receptor and A 2 (particularly A 2a ) receptor dual antagonists) and for the prevention and/or the treatment of depression, dementia (e.g.
  • the pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in a solid, semisolid or liquid form, which contains the pyrazolopyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
  • a pharmaceutical preparation for example, in a solid, semisolid or liquid form, which contains the pyrazolopyrazine compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient in admixture with an organic or inorganic carrier or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.
  • the active ingredient may be compounded, for example, with the usual non- toxic, pharmaceutically acceptable carriers for tablets, pellets, troches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use.
  • auxiliary, stabilizing agents, thickening agents, coloring agents and perfumes may be used where necessary.
  • the pyrazolopyrazine compound (I) or a pharmaceutically acceptable salt thereof is included in a pharmaceutical composition in an amount sufficient to produce the desired aforesaid pharmaceutical effect upon the process or condition of diseases.
  • the composition For applying the composition to a human being or an animal, it is preferable to apply it by intravenous, intramuscular, pulmonary or oral administration, or insufflation. While the dosage of therapeutically effective amount of the pyrazolopyrazine compound (I) varies depending on the age and condition of each individual patient to be treated, in the case of intravenous administration, a daily dose of 0.01 - 100 mg of the pyrazolopyrazine compound (I) per kg weight of a human being or an animal, in the case of intramuscular administration, a daily dose of 0.1 - 100 mg of the pyrazolopyrazine compound (I) per kg weight of a human being or an animal, and in case of oral administration, a daily dose of 0.5 - 100 mg of the pyrazolopyrazine compound (I) per kg weight of a human being or an animal is generally given for the prevention and/or treatment of the aforesaid diseases.
  • Trifluoromethanesulfonic acid 6-benzene-sulfonylpyridazin-3-yl ester (200 g) was obtained by filtration.
  • Example 1 3- [2- (2-Thenyl) -3-OXO-2, 3-dihydropyridazin-6-yl] -2- phenylpyrazolo [1, 5-a] pyrazine was obtained in a similar manner to that of Example 3.
  • NMR (DMSO-d6, ⁇ ): 5.55(2H,s), 6.96 ( IH, d, J 9.7Hz) , 7.01-
  • Example 15 3- [2- (4-Tetrahydropyranyl) -3-oxo-2, 3-dihydropyridazin-6- yl] -2-phenylpyrazolo [ 1, 5-a] pyrazine was obtained in a similar manner to that of Example 3. mp: 217-218°C (AcOEt-hexane)
  • Example 28 3- (2-Isopropyl-3-oxo-2, 3-dihydropyridazin-6-yl) -2- (4- chlorophenyl) pyrazolo [ 1, 5-a] pyrazine was obtained in a similar manner to that of Example 2. mp: 167-169°C (EtOH)
  • N, N-dimethylformamide (6 ml) was added 60%-sodium hydroxide (74 mg) at ambient temperature. After stirring for 1 h, isopropyl iodide (0.25 ml) was added to the mixture which was stirred 16 hours . The mixture was partitioned between water and ethyl acetate .
  • Example 31 3- (2-Methyl-3-oxo-2, 3-dihydropyridazin-6-yl ) -2- (3- chlorophenyl) pyrazolo [1, 5-a] pyrazine was obtained in a similar manner to that of Example 2. mp: 239-241°C (AcOEt)
  • Example 33 3- [2- (4-Tetrahydropyranyl) -3-oxo-2, 3-dihydropyridazin-6- yl] -2- (3-chlorophenyl ) pyrazolo [ 1 , 5-a] pyrazine was obtained in a similar manner to that of Example 3. mp: 153-155°C (EtOH)
  • Example 36 3- (3-Oxo-2 , 3-dihydropyridazin-6-yl) -2- (2-fluorophenyl ) pyrazolo [1, 5-a] pyrazine was obtained in a similar manner to that of Example 1. mp: >250°C (CHC1 3 , MeOH)
  • 6-yl) -2- (3-fluorophenyl) pyrazolo [1, 5-a] pyrazine 400 mg
  • N, N-dimethylformamide 5 ml
  • 60%-sodium hydroxide 78 mg
  • isopropyl iodide (0.26 ml) was added to the mixture which was stirred 16 hours .
  • the mixture was partitioned between water and ethyl acetate .
  • N,N-dimethylformamide 200 ml was added 60%-sodium hydroxide (2.93 g) at ambient temperature. After stirring for 1 h, isopropyl iodide ( 9.7 ml ) was added to the mixture which was stirred 16 hours .
  • Example 62 3- [2- (3, 3, 3-Trifluoropropyl) -3-oxo-2, 3-dihydropyridazin- 6-yl] -2-phenylpyrazolo [1, 5-a] pyrazine was obtained in a similar manner to that of Example 61.
  • Example 74 3- (2-Isopropyl-3-oxo-2, 3-dihydropyridazin-6-yl) -2- (3-fluoro- 4-hydroxyphenyl) pyrazolo [1, 5-a] pyrazine can be obtained in a similar manner to that of Example 22.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de pyrazolopyrazine représenté par la formule (I), dans laquelle R1 est aryle pouvant avoir un ou plusieurs substituants appropriés; et R2 est hydrogène; alkyle inférieur; alcényle inférieur; cycloalkyle inférieur; un groupe hétéromonocyclique; alkyle inférieur substitué par un ou plusieurs substituants pouvant être cycloalkyle inférieur, halogène, cyano, aryle et un groupe hétéromonocyclique, ou un sel correspondant. Le composé de pyrazolopyrazine de formule (I), ou un sel correspondant, est un antagoniste vis-à-vis de l'adénosine, utile pour la prévention et/ou le traitement de la dépression, de la démence (par exemple, maladie d'Alzheimer, démence par accident vasculaire cérébral, démence accompagnant la maladie de Parkinson, etc.), de la maladie de Parkinson, de l'anxiété, de la douleur, des accidents vasculaires cérébraux (par exemple, attaques, etc.), de l'insuffisance cardiaque et autres affections.
PCT/JP2000/008008 1999-12-02 2000-11-13 Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine WO2001040230A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00974973A EP1244669A1 (fr) 1999-12-02 2000-11-13 Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine
AU13093/01A AU1309301A (en) 1999-12-02 2000-11-13 Pyrazolopyrazines and their use as adenosine antagonists
JP2001540985A JP2003515537A (ja) 1999-12-02 2000-11-13 ピラゾロピラジンおよびそのアデノシン拮抗剤としての利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4414A AUPQ441499A0 (en) 1999-12-02 1999-12-02 Novel compound
AUPQ4414 1999-12-02

Publications (1)

Publication Number Publication Date
WO2001040230A1 true WO2001040230A1 (fr) 2001-06-07

Family

ID=3818556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/008008 WO2001040230A1 (fr) 1999-12-02 2000-11-13 Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine

Country Status (5)

Country Link
EP (1) EP1244669A1 (fr)
JP (1) JP2003515537A (fr)
AR (1) AR026470A1 (fr)
AU (1) AUPQ441499A0 (fr)
WO (1) WO2001040230A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066020A2 (fr) * 2001-02-21 2002-08-29 Can-Fite Biopharma Ltd. Modulation de l'activite de gsk-3beta et ses differentes utilisations
WO2002100864A1 (fr) * 2001-06-06 2002-12-19 Fujisawa Pharmaceutical Co., Ltd. Compose de pyrazolopyrazine et utilisation pharmaceutique
WO2003004494A1 (fr) * 2001-07-02 2003-01-16 Fujisawa Pharmaceutical Co., Ltd. Composes de pyridazinone utiles comme antagonistes de l'adenosine
WO2003039451A2 (fr) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Derive de thiazole et utilisation pharmaceutique
WO2006021805A1 (fr) * 2004-08-27 2006-03-02 Merck Sharp & Dohme Limited Diarylsulfones employées en tant qu'antagonistes du récepteur 5-ht2a
WO2006038734A1 (fr) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Dérivés de la pyridazinone inhibiteurs de cytokines
WO2007026950A1 (fr) * 2005-09-01 2007-03-08 Astellas Pharma Inc. Nouveaux composes
WO2007045705A2 (fr) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Composes servant a traiter la fibrillation auriculaire
EP2044940A2 (fr) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Procédé de traitement de patients ayant des troubles du mouvement
US7968572B2 (en) 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
ES2544869A1 (es) * 2014-03-04 2015-09-04 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
CN113939295A (zh) * 2019-03-20 2022-01-14 金翅雀生物公司 哒嗪酮及其使用方法
CN114126620A (zh) * 2019-05-13 2022-03-01 传达治疗有限公司 Fgfr抑制剂和其使用方法
CN114630830A (zh) * 2019-10-31 2022-06-14 治愈医药社株式会社 新型化合物及包含其的用于预防或治疗癌症的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379979A1 (fr) * 1989-01-23 1990-08-01 Fujisawa Pharmaceutical Co., Ltd. Composés pyrazolopyridiniques et procédés pour sa préparation
EP0467248A2 (fr) * 1990-07-18 1992-01-22 Fujisawa Pharmaceutical Co., Ltd. Composé de pyrazolopyridine et procédés pour sa préparation
US5773530A (en) * 1993-12-29 1998-06-30 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0379979A1 (fr) * 1989-01-23 1990-08-01 Fujisawa Pharmaceutical Co., Ltd. Composés pyrazolopyridiniques et procédés pour sa préparation
EP0467248A2 (fr) * 1990-07-18 1992-01-22 Fujisawa Pharmaceutical Co., Ltd. Composé de pyrazolopyridine et procédés pour sa préparation
US5773530A (en) * 1993-12-29 1998-06-30 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066020A2 (fr) * 2001-02-21 2002-08-29 Can-Fite Biopharma Ltd. Modulation de l'activite de gsk-3beta et ses differentes utilisations
WO2002066020A3 (fr) * 2001-02-21 2003-01-03 Can Fite Biopharma Ltd Modulation de l'activite de gsk-3beta et ses differentes utilisations
WO2002100864A1 (fr) * 2001-06-06 2002-12-19 Fujisawa Pharmaceutical Co., Ltd. Compose de pyrazolopyrazine et utilisation pharmaceutique
US7030121B2 (en) 2001-06-06 2006-04-18 Astellas Pharma Inc. Pyrazolopyrazine compound and pharmaceutical use thereof
WO2003004494A1 (fr) * 2001-07-02 2003-01-16 Fujisawa Pharmaceutical Co., Ltd. Composes de pyridazinone utiles comme antagonistes de l'adenosine
WO2003039451A2 (fr) * 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Derive de thiazole et utilisation pharmaceutique
WO2003039451A3 (fr) * 2001-11-08 2003-09-25 Fujisawa Pharmaceutical Co Derive de thiazole et utilisation pharmaceutique
EP2942082A2 (fr) 2002-01-28 2015-11-11 Kyowa Hakko Kogyo Co., Ltd Antagonistes des récepteurs A2A pour utilisation dans le traitement des troubles du mouvement
EP2260850A2 (fr) 2002-01-28 2010-12-15 Kyowa Hakko Kogyo Co., Ltd Antagonistes des récepteurs A2A pour utilisation dans le traitement des troubles du mouvement
EP2044940A2 (fr) 2002-01-28 2009-04-08 Kyowa Hakko Kogyo Co., Ltd Procédé de traitement de patients ayant des troubles du mouvement
US7468393B2 (en) 2004-08-27 2008-12-23 Merck Sharp & Dohme Ltd. Diarylsulfones as 5-HT2A antagonists
AU2005276233B2 (en) * 2004-08-27 2011-03-17 Merck Sharp & Dohme Limited Diarylsulfones as 5-HT2A antagonists
WO2006021805A1 (fr) * 2004-08-27 2006-03-02 Merck Sharp & Dohme Limited Diarylsulfones employées en tant qu'antagonistes du récepteur 5-ht2a
US7217740B2 (en) 2004-08-27 2007-05-15 Merck Sharp And Dohme Diarylsulfones as 5-HT2A antagonists
WO2006038734A1 (fr) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Dérivés de la pyridazinone inhibiteurs de cytokines
CN101268079B (zh) * 2005-09-01 2011-09-14 安斯泰来制药有限公司 用于治疗疼痛的哒嗪酮衍生物
WO2007026950A1 (fr) * 2005-09-01 2007-03-08 Astellas Pharma Inc. Nouveaux composes
US7968572B2 (en) 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
WO2007045705A2 (fr) 2005-10-14 2007-04-26 Proyecto De Biomedicina Cima, S.L. Composes servant a traiter la fibrillation auriculaire
ES2544869A1 (es) * 2014-03-04 2015-09-04 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
CN113939295A (zh) * 2019-03-20 2022-01-14 金翅雀生物公司 哒嗪酮及其使用方法
CN114126620A (zh) * 2019-05-13 2022-03-01 传达治疗有限公司 Fgfr抑制剂和其使用方法
EP3968999A4 (fr) * 2019-05-13 2022-08-03 Relay Therapeutics, Inc. Inhibiteurs de fgfr et leurs procédés d'utilisation
US11780845B2 (en) 2019-05-13 2023-10-10 Relay Therapeutics, Inc. FGFR inhibitors and methods of use thereof
EP4306529A3 (fr) * 2019-05-13 2024-04-10 Relay Therapeutics, Inc. Inhibiteurs de fgfr et leurs procédés d'utilisation
CN114630830A (zh) * 2019-10-31 2022-06-14 治愈医药社株式会社 新型化合物及包含其的用于预防或治疗癌症的药物组合物

Also Published As

Publication number Publication date
AUPQ441499A0 (en) 2000-01-06
JP2003515537A (ja) 2003-05-07
AR026470A1 (es) 2003-02-12
EP1244669A1 (fr) 2002-10-02

Similar Documents

Publication Publication Date Title
US5204346A (en) Pyrazolopyridine compounds
EP2788000B1 (fr) Pyrrolopyrimidines en tant qu'inhibiteurs de kinase janus
CN110062758B (zh) 作为rho-激酶抑制剂的二环二氢嘧啶-甲酰胺衍生物
EP3080120B1 (fr) Dérivés imidazole et pyrazole condenses utilisables en tant que modulateurs de l'activité tnf
TWI433850B (zh) 可用於治療ｃｎｓ症狀之新化合物
JP2020128418A (ja) 抗線維性ピリジノン
EP1140929B1 (fr) 1h-imidazo 4,5-d]pyridazine-7-ones, 3h-imidazo 4,5-c]pyridine-4-ones et thiones correspondants convenant comme ligands du recepteur de la corticoliberine
JPH07252256A (ja) 新規複素環誘導体
US6579876B2 (en) Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
EP1244669A1 (fr) Pyrazolopyrazines et leur utilisation comme antagonistes vis-a-vis de l'adenosine
EP0994877A1 (fr) Imidazopyrimidines et imidazopyridines utiles pour traiter des troubles neurologiques
KR20020038941A (ko) 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-ｄ]피리미딘-7-온
AU2023254866A1 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
WO2004016605A1 (fr) Derives de 2-aminopyrimidine utilises en tant qu'antagonistes des recepteurs a2a et a1 de l'adenosine
EP0228006A1 (fr) Composés d'imidazopyridine et procédés pour leur préparation
WO2003057689A1 (fr) Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
US20230065034A1 (en) Crf receptor antagonists and methods of use
EP2576537B1 (fr) Dérivés de 2-amino-pyrimidine utiles en tant qu'inhibiteurs de la jnk
WO2003004494A1 (fr) Composes de pyridazinone utiles comme antagonistes de l'adenosine
US20040152706A1 (en) Pyrazolopyrazine compound pharmaceutical use thereof
WO2004089939A1 (fr) Derives de furan condense utilises en tant qu'antagonistes d'adenosine
CA2902038C (fr) Inhibiteurs de tyrosine kinase de bruton

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 540985

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10148572

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000974973

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000974973

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000974973

Country of ref document: EP